Axogen, Inc. (AXGN): Price and Financial Metrics

Axogen, Inc. (AXGN): $7.71

0.03 (+0.39%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

AXGN Price/Volume Stats

Current price $7.71 52-week high $10.83
Prev. close $7.68 52-week low $3.45
Day low $7.50 Volume 360,500
Day high $7.88 Avg. volume 464,562
50-day MA $9.29 Dividend yield N/A
200-day MA $7.32 Market Cap 333.12M

AXGN Stock Price Chart Interactive Chart >

AXGN POWR Grades

  • AXGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.26% of US stocks.
  • The strongest trend for AXGN is in Stability, which has been heading down over the past 26 weeks.
  • AXGN ranks lowest in Momentum; there it ranks in the 4th percentile.

AXGN Stock Summary

  • AXGN has a market capitalization of $285,379,108 -- more than approximately 31.16% of US stocks.
  • AXOGEN INC's stock had its IPO on March 27, 1990, making it an older stock than 84.83% of US equities in our set.
  • In terms of volatility of its share price, AXGN is more volatile than 82.57% of stocks we're observing.
  • Stocks that are quantitatively similar to AXGN, based on their financial statements, market capitalization, and price volatility, are WRAP, REFR, ECOR, ASPN, and HEAR.
  • Visit AXGN's SEC page to see the company's official filings. To visit the company's web site, go to www.axogeninc.com.

AXGN Valuation Summary

  • AXGN's price/earnings ratio is -12.7; this is 143.57% lower than that of the median Healthcare stock.
  • AXGN's price/earnings ratio has moved down 10.9 over the prior 243 months.

Below are key valuation metrics over time for AXGN.

Stock Date P/S P/B P/E EV/EBIT
AXGN 2023-12-29 1.9 3.0 -12.7 -14.7
AXGN 2023-12-28 1.9 3.0 -12.7 -14.8
AXGN 2023-12-27 2.0 3.1 -12.9 -15.0
AXGN 2023-12-26 2.0 3.1 -13.2 -15.3
AXGN 2023-12-22 2.0 3.1 -13.0 -15.1
AXGN 2023-12-21 2.0 3.1 -13.2 -15.3

AXGN Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -29.51%.
  • The 4 year net income to common stockholders growth rate now stands at -91.93%.
  • Its 4 year cash and equivalents growth rate is now at 61.67%.
Over the past 67 months, AXGN's revenue has gone up $88,720,148.

The table below shows AXGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 133.957 -18.942 -28.819
2022-06-30 128.202 -18.629 -31.642
2022-03-31 127.328 -13.636 -31.8
2021-12-31 127.358 -13.405 -26.985
2021-09-30 128.316 -9.054 -27.709
2021-06-30 130.54 -6.06 -22.047

AXGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AXGN has a Quality Grade of C, ranking ahead of 50.98% of graded US stocks.
  • AXGN's asset turnover comes in at 0.65 -- ranking 58th of 186 Medical Equipment stocks.
  • ADMT, NDRA, and APYX are the stocks whose asset turnover ratios are most correlated with AXGN.

The table below shows AXGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.650 0.821 -0.111
2021-03-31 0.625 0.816 -0.133
2020-12-31 0.633 0.808 -0.172
2020-09-30 0.651 0.806 -0.219
2020-06-30 0.661 0.808 -0.294
2020-03-31 0.706 0.829 -0.278

AXGN Price Target

For more insight on analysts targets of AXGN, see our AXGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.00 Average Broker Recommendation 1.43 (Moderate Buy)

Axogen, Inc. (AXGN) Company Bio


AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company is based in Alachua, Florida.


AXGN Latest News Stream


Event/Time News Detail
Loading, please wait...

AXGN Latest Social Stream


Loading social stream, please wait...

View Full AXGN Social Stream

Latest AXGN News From Around the Web

Below are the latest news stories about AXOGEN INC that investors may wish to consider to help them evaluate AXGN as an investment opportunity.

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Weiler brings 20+ years of strategic and commercial leadership experience to the Axogen, Inc. Board of DirectorsALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven

Yahoo | December 26, 2023

Axogen Announces Transition of Finance Team Leadership

Nir Naor Appointed CFO to Replace Peter Mariani as Company Aligns Executive Team with Financial Management Needs for Next Phase of GrowthALACHUA, Fla. and TAMPA, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Mr. Nir Naor as Chief Financial Officer, effective immediately. A senior finance executive with more than 20 years of experience

Yahoo | December 6, 2023

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ALACHUA and TAMPA, Fla., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of Harold D. Tamayo as Vice President of Finance and Investor Relations. Mr. Tamayo will report to Peter J. Mariani, Executive Vice President and Chief Financial Officer, and will

Yahoo | December 1, 2023

Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference

ALACHUA and TAMPA, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will present at the Piper Sandler 35th Annual Healthcare Conference in New York, NY, on Thursday, November 30, 2023, at 8:50 a.m. E.T. Webcast events can be accessed live through the Investors page at www.axogeninc.com. F

Yahoo | November 20, 2023

Great week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 51% over the previous year

Key Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the...

Yahoo | November 17, 2023

Read More 'AXGN' Stories Here

AXGN Price Returns

1-mo -27.26%
3-mo 9.21%
6-mo 48.27%
1-year -6.20%
3-year -64.09%
5-year -62.41%
YTD 12.88%
2023 -31.56%
2022 6.51%
2021 -47.65%
2020 0.06%
2019 -12.43%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!